Early improvement of psychotic symptoms with lithium monotherapy as a predictor of later response in mania

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSOUSA, Rafael T. de
dc.contributor.authorBUSNELLO, Joao V.
dc.contributor.authorFORLENZA, Orestes V.
dc.contributor.authorZANETTI, Marcus V.
dc.contributor.authorSOEIRO-DE-SOUZA, Marcio G.
dc.contributor.authorBILT, Martinus T. van de
dc.contributor.authorMORENO, Ricardo A.
dc.contributor.authorZARATE JR., Carlos A.
dc.contributor.authorGATTAZ, Wagner F.
dc.contributor.authorMACHADO-VIEIRA, Rodrigo
dc.date.accessioned2013-07-30T15:18:59Z
dc.date.available2013-07-30T15:18:59Z
dc.date.issued2012
dc.description.abstractAlthough lithium has been the first line agent in the treatment of bipolar disorder (BD), few studies have evaluated lithium's efficacy in mania with psychosis and its association with later response. Furthermore, given the widespread concern about antipsychotic side effects, answering a question about whether lithium alone can manage to treat both psychotic and non-psychotic mania seems a very relevant one. The present study addresses the antipsychotic efficacy of lithium monotherapy in acute mania and early improvement of psychotic symptoms as a predictor of later response of manic symptoms. Forty-six patients presenting a manic episode (32 with psychotic features and 14 subjects without psychotic features) were treated for 4 weeks with lithium monotherapy and evaluated weekly using the Young Mania Rating Scale (YMRS). Subjects with rapid cycling, substance abuse/dependence, or mixed episodes were excluded. The overall antimanic efficacy of lithium in psychosis vs. non-psychosis groups was evaluated. In addition, early improvement of psychotic symptoms and its prediction of subsequent response (>50% decrease in total YMRS scores) or remission were evaluated. Lithium showed a similar efficacy in both psychosis and non-psychosis mania. Early improvement of psychotic symptoms was associated with clinical response and remission at endpoint.
dc.description.indexMEDLINE
dc.description.sponsorshipStanley Medical Research Institute [03T-356]
dc.identifier.citationJOURNAL OF PSYCHIATRIC RESEARCH, v.46, n.12, p.1564-1568, 2012
dc.identifier.doi10.1016/j.jpsychires.2012.08.011
dc.identifier.issn0022-3956
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/1108
dc.language.isoeng
dc.publisherPERGAMON-ELSEVIER SCIENCE LTD
dc.relation.ispartofJournal of Psychiatric Research
dc.rightsrestrictedAccess
dc.rights.holderCopyright PERGAMON-ELSEVIER SCIENCE LTD
dc.subjectPsychosis
dc.subjectMania
dc.subjectLithium
dc.subjectEarly improvement
dc.subjectMonotherapy
dc.subject.otherbipolar disorder
dc.subject.otherdouble-blind
dc.subject.otherplacebo
dc.subject.otherefficacy
dc.subject.otherrecommendations
dc.subject.otherantipsychotics
dc.subject.otherschizophrenia
dc.subject.otherspecificity
dc.subject.otherguidelines
dc.subject.otherillness
dc.subject.wosPsychiatry
dc.titleEarly improvement of psychotic symptoms with lithium monotherapy as a predictor of later response in mania
dc.typearticle
dc.type.categoryoriginal article
dc.type.versionpublishedVersion
dspace.entity.typePublication
hcfmusp.affiliation.countryEstados Unidos
hcfmusp.affiliation.countryisous
hcfmusp.author.externalBUSNELLO, Joao V.:Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA
hcfmusp.author.externalZARATE JR., Carlos A.:NIMH, Sect Neurobiol & Treatment Mood Disorders, Intramural Res Program, Bethesda, MD 20892 USA
hcfmusp.citation.scopus10
hcfmusp.contributor.author-fmusphcRAFAEL AUGUSTO TEIXEIRA DE SOUSA
hcfmusp.contributor.author-fmusphcORESTES VICENTE FORLENZA
hcfmusp.contributor.author-fmusphcMARCUS VINICIUS ZANETTI
hcfmusp.contributor.author-fmusphcMARCIO GERHARDT SOEIRO DE SOUZA
hcfmusp.contributor.author-fmusphcMARTINUS THEODORUS VAN DE BILT
hcfmusp.contributor.author-fmusphcRICARDO ALBERTO MORENO
hcfmusp.contributor.author-fmusphcWAGNER FARID GATTAZ
hcfmusp.contributor.author-fmusphcRODRIGO MACHADO VIEIRA
hcfmusp.description.beginpage1564
hcfmusp.description.endpage1568
hcfmusp.description.issue12
hcfmusp.description.volume46
hcfmusp.lim.ref2012
hcfmusp.origemWOS
hcfmusp.origem.pubmed23000368
hcfmusp.origem.scopus2-s2.0-84868119057
hcfmusp.origem.wosWOS:000311983100005
hcfmusp.publisher.cityOXFORD
hcfmusp.publisher.countryENGLAND
hcfmusp.relation.referenceBora E, 2010, J AFFECT DISORDERS, V127, P1, DOI 10.1016/j.jad.2010.02.117
hcfmusp.relation.referenceBowden CL, 2005, J CLIN PSYCHIAT, V66, P111
hcfmusp.relation.referenceCoryell W, 2001, J AFFECT DISORDERS, V67, P79, DOI 10.1016/S0165-0327(99)00024-5
hcfmusp.relation.referenceFirst M.B., 2001, STRUCTURED CLIN INTE
hcfmusp.relation.referenceGoodwin GM, 2009, J PSYCHOPHARMACOL, V23, P346, DOI 10.1177/0269881109102919
hcfmusp.relation.referenceGrandjean EM, 2009, CNS DRUGS, V23, P225, DOI 10.2165/00023210-200923030-00004
hcfmusp.relation.referenceHouston John P, 2010, BMC Res Notes, V3, P276, DOI 10.1186/1756-0500-3-276
hcfmusp.relation.referenceKeck PE, 2009, J AFFECT DISORDERS, V112, P36, DOI 10.1016/j.jad.2008.05.014
hcfmusp.relation.referenceKeck PE, 2003, COMPR PSYCHIAT, V44, P263, DOI 10.1016/S0010-440X(03)00089-0
hcfmusp.relation.referenceKemp DE, 2011, J CLIN PSYCHIAT, V72, P1236, DOI 10.4088/JCP.09m05874yel
hcfmusp.relation.referenceKemp DE, 2011, J AFFECT DISORDERS, V130, P171, DOI 10.1016/j.jad.2010.10.026
hcfmusp.relation.referenceKetter TA, 2010, J PSYCHIATR RES, V44, P8, DOI 10.1016/j.jpsychires.2009.07.006
hcfmusp.relation.referenceKinon BJ, 2008, SCHIZOPHR RES, V102, P230, DOI 10.1016/j.schres.2008.02.021
hcfmusp.relation.referenceMachado-Vieira R, 2008, J CLIN PSYCHIAT, V69, P1237
hcfmusp.relation.referenceMalhi GS, 2009, ACTA PSYCHIAT SCAND, V119, P27, DOI 10.1111/j.1600-0447.2009.01383.x
hcfmusp.relation.referenceMcElroy SL, 1996, J CLIN PSYCHIAT, V57, P14
hcfmusp.relation.referencePOPE HG, 1978, ARCH GEN PSYCHIAT, V35, P811
hcfmusp.relation.referencePRIEN RF, 1972, ARCH GEN PSYCHIAT, V26, P146
hcfmusp.relation.referenceSMALL JG, 1995, PSYCHOPHARMACOL BULL, V31, P265
hcfmusp.relation.referenceSwann AC, 2002, NEUROPSYCHOPHARMACOL, V26, P530, DOI 10.1016/S0893-133X(01)00390-6
hcfmusp.relation.referenceSwann AC, 2004, J CLIN PSYCHIAT, V65, P825
hcfmusp.relation.referenceSzegedi A, 2009, J CLIN PSYCHIAT, V70, P344
hcfmusp.relation.referenceTOHEN M, 1990, ARCH GEN PSYCHIAT, V47, P1106
hcfmusp.relation.referenceYatham LN, 2009, BIPOLAR DISORD, V11, P225, DOI 10.1111/j.1399-5618.2009.00672.x
hcfmusp.relation.referenceYOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429
hcfmusp.remissive.sponsorshipStanley
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication9fc9d7cc-a262-4fb6-a447-fbc1dad7c205
relation.isAuthorOfPublication5d22f916-9e62-48bf-99aa-65b7cb87cb46
relation.isAuthorOfPublicationc0e3a2b2-9a34-4116-9da9-75bec7265484
relation.isAuthorOfPublicationd4177e75-4bef-4197-aab9-f201f8b97e5c
relation.isAuthorOfPublicatione66f1d29-2fed-4486-a0ab-6de56f685ce8
relation.isAuthorOfPublicatione8e981a1-ce9f-425e-8ef5-6d83f88f3cbd
relation.isAuthorOfPublication125dcc9f-a05a-42fd-ab1d-b6db35d2616b
relation.isAuthorOfPublication87bd8384-b428-475b-b25d-011a60f9d83c
relation.isAuthorOfPublication.latestForDiscovery9fc9d7cc-a262-4fb6-a447-fbc1dad7c205
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
art_SOUSA_Early_improvement_of_psychotic_symptoms_with_lithium_monotherapy_2012.PDF
Tamanho:
220.86 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27